Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK in first for human heart valve grown from stem cells:

This article was originally published in Clinica

Executive Summary

A UK team has created what is claimed to be the first human heart valve to be grown from stem cells. The investigators, from the Harefield Heart Science Centre near London, first used chemical and physical nudges to coax stem cells extracted from bone marrow to grow into heart valve cells, according to an article published in The Guardian (April 2). The cells were then placed on collagen scaffolds and grown into 3cm-wide discs of heart valve tissue. The valves are expected to be tested in animals later this year. In a comment by the British Heart Foundation, Professor John Martin said: "Although the work carried out the Harefield is exciting, there is a long road to be travelled before patients awaiting heart transplants will benefit from this research."

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT048005

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel